Healthium Medtech ropes in Rajnish Damani as Group COO

IMT News Desk
IMT News Desk
· 2 min read

Damani will oversee manufacturing, R&D and supply chain operations across the group

Healthium Medtech has appointed Rajnish Damani as Group Chief Operating Officer (COO). Damani will oversee Manufacturing, R&D, and Supply Chain operations across the Group, reporting directly to the CEO and MD, Anish Bafna.

By bringing all manufacturing units, supply chain functions and R&D under a unified leadership structure, the company aims to optimise processes, elevate execution and enhance service to patients and healthcare partners globally.

Bafna said, “Damani’s deep cross-sectoral experience and ability to drive complex transformations make him the right leader to steer this next phase. His sharp execution focus and people-first approach will help us unlock new levels of performance and innovation. We are confident that this new organisational framework will propel us toward achieving our strategic objectives and ensure even greater quality and responsiveness in our offerings.”

Damani joins Healthium with over 32 years of diverse experience across manufacturing, procurement, supply chain, quality and EHS. He has worked across sectors including automotive, healthcare, renewables, aviation, transportation, power and tire industries. Most recently, he served as Executive Director – Manufacturing Operations at Bridgestone India, where he led strategic manufacturing initiatives, including long-term investment planning, quality improvements, talent development and new product introductions. His previous roles include leadership positions at General Electric, Cummins and Hindustan Motors, with extensive experience managing multi-plant operations and complex industrial relations.

Damani holds a degree in Engineering from Birla Institute of Technology, Mesra and will be relocating from Pune to take up his new role at Healthium.

Damani said, “I look forward to working with Bafna and the leadership team to strengthen operational integration, foster innovation and build agile, scalable systems that deliver excellence across the value chain.”

Read Next

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris
News
June 12, 2026

Glenmark Launches Winlevi® in Key European Markets for the Treatment of Acne Vulgaris

Glenmark Specialty S.A. (GSSA), a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd., has announced the launch of Winlevi® (clascoterone 10 mg/g cream) across key markets in Europe. This follows the grant of marketing authorization of the product for the treatment of acne vulgaris in both adults and adolescents aged 12 to <18 years (with usage in […]
Article by: IMT News Desk
Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory
News
June 12, 2026

Thyrocare Expands Its Presence in Prayagraj with the Launch of Its New Diagnostic Laboratory

Thyrocare Technologies Limited has announced the set-up of its new diagnostic laboratory in Prayagraj, Uttar Pradesh, in association with SecondMedic. The new laboratory is equipped with advanced testing infrastructure and supported by trained professionals, enabling timely and error-free diagnostic results. It caters to both specialised and routine testing requirements, offering support to ongoing and preventive […]
Article by: IMT News Desk
AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer
News
June 12, 2026

AstraZeneca Gets CDSCO Approval for Trastuzumab Deruxtecan in HER2-Positive Breast Cancer

AstraZeneca Pharma India Ltd. (AZPIL) announced that the Central Drugs Standard Control Organisation (CDSCO) has approved an additional indication for Trastuzumab Deruxtecan 100 mg/5 mL vial lyophilized powder for concentrate for solution for infusion, in combination with Pertuzumab as a first-line treatment for adult patients with unresectable or metastatic HER2-positive (IHC 3+ or ISH+) breast cancer. In India, HER2-positive breast […]
Article by: IMT News Desk
Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules
News
June 11, 2026

Alembic Pharmaceuticals Limited announces USFDA Tentative Approval for Larotrectinib Capsules

Alembic Pharmaceuticals Limited (Alembic) announced that it has received tentative approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Larotrectinib Capsules, 25 mg and 100 mg. The approved ANDA is therapeutically equivalent to the reference listed drug product (RLD), Vitrakvi Capsules, 25 mg and 100 mg, of […]
Article by: IMT News Desk